Revival? Prospects for a return to comprehensive and coordinated health technology assessment in America

Expert Rev Pharmacoecon Outcomes Res. 2024 Jan;24(1):11-13. doi: 10.1080/14737167.2023.2279725. Epub 2024 Jan 18.

Author

Daniel A Ollendorf¹

Affiliation

¹ Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research & Health Policy Studies, Tufts Medical Center, Boston, MA, USA.

PMID: 37925648
DOI: 10.1080/14737167.2023.2279725

No abstract available

Keywords: Cost-effectiveness analysis; Health care costs; Health technology assessment; Pharmaceutical pricing; United States.

Publication types

Editorial

MeSH terms

Costs and Cost Analysis
Drug Costs*
Humans
Technology Assessment, Biomedical*